SCHEMBL12065621

SCHEMBL12065621

Fc1ccc2[nH]c(C(OC3CCCCC3)c3ccc(OC(F)(F)F)cc3)nc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 1/20 0.36
▸ TRPA1 O75762 2/20 0.35
▸ TRPV1 Q8NER1 1/20 0.34
▸ TRPV4 Q9HBA0 1/20 0.34
▸ PDE2A O00408 6/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ PRKD3 O94806 1/20 0.33
▸ PRKCG P05129 1/20 0.33
▸ PHKG2 P15735 1/20 0.33
▸ RPS6KB1 P23443 1/20 0.33
▸ MARK3 P27448 1/20 0.33
▸ PRKCI P41743 1/20 0.33
▸ CLK2 P49760 1/20 0.33
▸ IRAK1 P51617 1/20 0.33
▸ RPS6KA3 P51812 1/20 0.33
▸ PRKCD Q05655 1/20 0.33
▸ MAP4K2 Q12851 1/20 0.33
▸ STK3 Q13188 1/20 0.33
▸ CAMK2B Q13554 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770497 0.88 MLKL (0.37) —
SCHEMBL14762836 0.83 MLKL (0.48) SCN10ATRPA1TRPV1TRPV4PDE2A
SCHEMBL12066063 0.81 SCN10A (0.38) SCN10ATRPA1TRPV1TRPV4PDE2A
SCHEMBL14762782 0.81 SCN10A (0.43) SCN10ATRPA1TRPV1TRPV4PDE2A
SCHEMBL12065615 0.80 SCN10A (0.38) SCN10ATRPA1TRPV1TRPV4PDE2A
SCHEMBL12065645 0.80 SCN10A (0.38) SCN10ATRPA1PDE2AALPLALPI
SCHEMBL12065255 0.80 SCN10A (0.40) SCN10ATRPA1TRPV1TRPV4PDE2A
SCHEMBL12065659 0.78 SCN10A (0.39) SCN10ATRPA1TRPV1TRPV4PDE2A
SCHEMBL12065641 0.78 ALPL (0.38) SCN10ATRPA1TRPV1TRPV4PDE2A
SCHEMBL12065245 0.78 ALPL (0.44) SCN10ATRPA1TRPV1TRPV4PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed
WO-2011148956-A1 FUSED IMIDAZOLE DERIVATIVE トーアエイヨー株式会社 (JP) 2011-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A SCN10A 85/4885TRPA1 58/4885TRPV1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback